文献速递外周动脉疾病

紫杉醇洗脱球囊治疗股腘动脉支架内再狭窄的18个月结局:PLAISIR试验

Femoropopliteal In-stent Restenosis Repair: Midterm Outcomes After Paclitaxel Eluting Balloon Use (PLAISIR Trial).
PubMed 文献 · Eur J Vasc Endovasc Surg · 2016-11-24

PLAISIR是一项法国前瞻性多中心队列研究,纳入症状性股腘动脉支架内再狭窄患者,采用紫杉醇洗脱球囊(PEB)治疗,随访至18个月。共55条肢体接受手术,1年免于靶病变血运重建率90.2%,免于靶肢体血运重建率85%,一期通畅率83.7%,持续临床改善维持至18个月。结论认为PEB治疗股腘动脉支架内再狭窄再干预率低、再狭窄率低,临床改善可维持至18个月。

要点

  • PEB治疗股腘动脉支架内再狭窄1年免于TLR达90.2%。
  • 1年一期通畅率83.7%,免于TER为85%。
  • 持续临床改善维持至18个月。

核心结论

  • 紫杉醇洗脱球囊治疗股腘动脉支架内再狭窄与低再干预率和低再狭窄率相关,临床改善可维持至18个月。

研究设计与样本

  • 法国前瞻性多中心队列研究,纳入2012年1月至2013年6月症状性股腘动脉支架内再狭窄患者,共53例患者、55条肢体接受紫杉醇洗脱球囊(In Pact Admiral)治疗。
  • 随访在1、3、6、9、12和18个月进行临床和双功超声评估,主要终点为12个月免于靶病变血运重建。

主要发现

  • 55条肢体中48条(87%)为间歇性跛行,7条(13%)为严重肢体缺血;PEB平均直径6±0.57 mm,平均长度86±32 mm,随访17个月(范围1-19)。
  • 1年生存率96±2.7%,免于TLR为90.2±4.2%,免于TER为85±5%,持续主要和次要临床改善分别为78.6±5.7%和92.0±3.8%。
  • 1年一期通畅率83.7±5.0%;术前EQ-5D平均评分66±14,1年时74±16(p=.10)。
  • 随访期间2例死亡,其中1例在术后33天死于肢体缺血。

临床怎么用

  • 对于股腘动脉支架内再狭窄的症状性患者,可考虑使用紫杉醇洗脱球囊治疗,以降低再干预和再狭窄风险。
  • 术后应在1、3、6、9、12和18个月进行临床和双功超声随访评估。

局限性

  • 研究为单臂队列,无对照组。
  • 样本量较小(53例患者、55条肢体)。
  • 10例患者因支架植入后超过2年发生再狭窄被判定为方案违背。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to assess 18 month outcomes of the paclitaxel eluting balloon (PEB) in patients with femoropopliteal (FP) in-stent restenosis (ISR). METHODS: In a national prospective and multicentre cohort study, symptomatic patients with femoropopliteal in-stent restenosis were included from January 2012 to June 2013. Patients were treated by paclitaxel eluting balloon angioplasty (In Pact Admiral, Medtronic, Santa Rosa, CA, USA). Clinical and duplex scan follow-up evaluations were performed at 1, 3, 6, 9, 12, and 18 months. The primary endpoint was freedom from target lesion revascularisation (TLR) at 12 months. Secondary endpoints were major adverse cardiovascular events (MACE), Target extremity revascularisation (TER), primary and secondary sustained clinical improvement, recurrent restenosis rate, primary and secondary patency, quality of life assessed by EQ-5D questionnaire, technical success, clinical success, and length of stay RESULTS: A total of 53 patients were enrolled. After a blinded review, 10 patients were defined as protocol violation because restenosis occurred more than 2 years after stent implantation. Procedures were performed in 55 limbs, 48 (87%) for claudication and 7 (13%) for critical limb ischaemia. The mean diameter and length of PEB were 6 ± 0.57 mm and 86 mm ± 32 mm, follow-up was 17 months (range 1-19). At 1 year, the survival rate was 96 ± 2.7% and freedom from TLR and TER were 90.2 ± 4.2% and 85 ± 5%, respectively. Sustained primary and secondary clinical improvements were 78.6 ± 5.7% and 92.0 ± 3.8%, respectively. At 1 year, the primary patency rate was 83.7 ± 5.0%. Prior to the procedure, the mean EQ-5D score was 66 ± 14 and 74 ± 16 at 1 year (p = .10). Two patients died during follow-up; one patient died 33 days after the procedure because of limb ischaemia. CONCLUSION: PEB for the treatment of FP ISR is associated with a low rate of re-interventions and restenosis. Clinical improvement is maintained at 18 months.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Bague N, Julia P, Sauguet A, et al. Femoropopliteal In-stent Restenosis Repair: Midterm Outcomes After Paclitaxel Eluting Balloon Use (PLAISIR Trial). Eur J Vasc Endovasc Surg. 2016. PMID: 27890526. doi:10.1016/j.ejvs.2016.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。